Recent reports have suggested that upregulation of programmed death-ligand 1 (PD-L1) in cancer is widely implicated in tumor immune evasion and is highly associated with tumor aggressiveness, which limits the effectiveness of anti-cancer agents [25]. This evidence concerns the gene CD274 and neoplasm.